Additionally, in the B16-F10 and YUMMER1.7 mouse models of malignant melanoma, combined treatment with CBL0137 (an activator of ZBP1) and an anti-PD-1 antibody (an immune checkpoint inhibitor) has been found to induce tumor regression [22] (Fig. 4D). The gene discussed is ZBP1; the disease is neoplasm.